Time to recognize an overlooked trait.

peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol Dial Transplant 12: 145–150, 1997 12. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC, International Expert Panel. Newonset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75[Suppl]: SS3– S24, 2003 13. Winkelmayer WC, Chandraker A: Pottransplantation anemia: Management and rationale. Clin J Am Soc Nephrol 3[Suppl 2]: S49–S55, 2008 14. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F: Prevalence and management of anemia in renal transplant recipients: A European survey. Am J Transplant 3: 835–845, 2003 15. Arbeiter K, Greenbaum L, Balzar E, Muller T, Hofmeister F, Bidmon B, Aufricht C. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol 14: 195–197, 2000 16. Al-Uzri A, Yorgin PD, Kling PJ: Anemia in children after transplantation: Etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 7: 253–264, 2003 17. Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE: Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 4: 2001–2006, 2004 18. Jaster R, Bittorf T, Klinken SP, Brock J: Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin. Biochem Pharmacol 51: 1181–1185, 1996